

2023
EUROPE
INTERCHANGE
COPENHAGEN | 26-27 APRIL



# State of the CDISC Standards Beyond CDISC 360

Presented by Bess LeRoy, Head of Standards Innovation, CDISC



## **Meet the Speaker**

Bess LeRoy

Title: Head of Standards Innovation

**Organization: CDISC** 

Bess LeRoy is the Head of Standards Development at CDISC. Bess has been a CDISC team member since 2011. She has over 15 years' experience working in public health research and has held positions at the Framingham Heart Study, the Rotterdam Study, the Arizona Cancer Center, and the Critical Path Institute.

Bess has a BS from the University of Michigan, an MPH from Boston University School of Public Health, and is currently a doctoral candidate at Johns Hopkins Bloomberg School of Public Health



## Agenda


- 1. What did we learn from CDISC 360?
- 2. How are CDISC Standards evolving?

### **Over 20 Years of CDISC Standards!**





## We Have Come a Long Way ....



BRIDG, CONTROLLED TERMINOLOGY AND GLOSSARY



#### **How Do CDISC Standards Continue to Evolve?**


- Standardize the meaning of the information
- Define the data processing (data flow)
- Provide machine-executable data flow definitions
- Standardize missing parts:
  - Protocol content
  - Collection instruments
  - Analysis / endpoint definitions and outputs
- Make standards less complex for the end users
- Publish standards from one trusted source





## **CDISC 360**

Piloted development of linked biomedical concept metadata to enable end to end automation






### **CDISC 360: Lessons Learned**

- Complete the end-to-end foundational standards where they are incomplete
- Enrich the foundational standards with the additional metadata needed for full data meaning and relationships by creating a biomedical concept layer
- Extend the CDISC Library model with implementation level metadata
- Collaborate with industry to standup and curate biomedical concepts










## **What are CDISC Biomedical Concepts?**

A pragmatic, iterative approach to creating biomedical concepts with a focus on providing tangible value for the CDISC community

#### **Key Objectives:**

- Reduce variability in standards implementations
- Increase metadata-driven automation
- Reduce barriers to operational implementation





## **Key Components of CDISC Biomedical Concepts**

Conceptual Layer Implementation Layer **Logical Data Model** 



### **Initial Use Cases**

Assessments	Screening	Weeks from starting treatment pathway <sup>b</sup>							
	-2"	0°	<b>2</b> <sup>c</sup>	3°	64	8'4	94	16".*	17
Informed consent	X								
Blood Tests <sup>gh</sup>	X							X	
ECG	X								
Medical History	X								
Physical and neurological assessment	X								
modified Toronto Clinical Neuropathy Score (mTCNS)	X								
Douleur Neuropathique 4 (DN4)	X								
Suicidal risk questionnaire	X								
Concomitant Medications	X	х	Х	X	X	X	Х	X	Х
Vital Signs <sup>1</sup>	X							X	
Pregnancy Test (for women of child bearing potential)		Xx		X	X		Х	X	
Randomisation (treatment allocation)		Xx							
Dispense Study Medication		X	X	X	X	X	X	X	
Pain Diaries <sup>i</sup>	X	X	X	X	X	X	X	X	
Tolerability scale		Xx			X			X	
Brief Pain Inventory-Modified Short Form (BPI-MSF)		Xx			X			X	
Insomnia Severity Index (ISI)		Xx			X			X	
Neuropathy Pain Symptom Inventory (NPSI)		Xx			X			X	
Hospital Anxiety and Depression Scale (HADS)		Xx			X			X	
RAND Short Form 36 (RAND SF-36)		Xx			X			X	
EQ-5D-5L		Xx			X			X	
Client Service Receipt Inventory (CSRI)		Xx			X			X	
Pain Catastrophising Scale (PCS)		Xx							
Adverse Events Assessment		X,	X	X	X	X	Х	X	Х
Compliance Assessment		X,	Х	X	Х	X	Х	Х	х

Retrieve a list of assessments for a study

VS (Vital Signs) - [SDTMIG 3.1.2]


Variable	Where Condition	Label / Description	Туре	Length or Display Format	Controlled Terms or ISO Format
VSORRES VLM		Result or Finding in Original Units	text	30	
	VSTESTCD = "DIABP" (Diastolic Blood Pressure)	Diastolic Blood Pressure in Orig U	integer	2	
	VSTESTCD = "FRMSIZE" (Body Frame Size)	Body Frame Size - Orig	text	6	Size - "SMALL" - "MEDIUM" - "LARGE"
	VSTESTCD = "HEIGHT" (Height)	Height in Orig U	float	5.1	

Publish BC content as Define-XML document including value level metadata



### **BC** Governance

- Light-weight CDISC curation and governance process
- 30-day Public Review
- Published quarterly
- Mechanism for community change requests



**Draft governance process** 





## **Learn more about BCs!**

Session 3: Track B- Biomedical Concepts

14:00 - 15:30



## **Analysis Results Standard Objectives**

- Use analysis results metadata to drive the automation of results
- Support storage, access, processing and reproducibility of results
- Improved navigation and reusability of analyses and results
- Traceability to Protocol/SAP and to input ADaM data



## **Analysis Results Standards Key Results**



Develop a technical specification to prospectively leverage Analysis Results Metadata to drive automation



Develop a structure to represent Analysis Results as data



Illustrate and exercise with a set of common data displays





## Learn more about ARS!

Session 5: Track A- Analysis Results Standard

9:00 - 10:30



#### **CDISC eCRF PORTAL**

- The eCRF Portal provides machine readable eCRFs
  - Visual representation of CRF layout with CDASH annotations
  - Machine-readable ODM format
- Includes CRFs from:
  - CDASH Implementation Guide v2.1
  - Crohn's Disease Therapeutic Area User Guide
  - Upcoming COVID-19 Therapeutic Area User Guide
  - 54 eCRFs to date



- Formedix offers the Ryze platform at no cost
- Used as a base to create OpenClinica and REDCap CRFs

## **Tobacco Implementation Guide (TIG) v1.0**

- Proactively designed to reflect use cases unique to tobacco product data
- A single, comprehensive implementation guide for tobacco product data submissions



An overview of standards and general implementation



Key scientific concepts and maps



Data Collection (CDASH eCRFs, ODM-XML)



Data Tabulation (SEND, SDTM Human Clinical, Define-XML)



Analysis (ADaM, Define-XML)

Product Description

and use cases; e.g.

With guidance by topics

- Nonclinical
- Individual Health
- Population Health



Common Language (Controlled Terminology)



Measures of Adherence (Conformance Rules)



Accessible in platforms which optimize use (including CDISC website, CDISC Library)













## Learn more about TIG!

Session 6: Track A- Updates Towards Regulatory

11:00 - 13:00



## **Foundational Standards Development 2023**

ADaM – Planning for a consolidated ADaMIG

SDS - Multiple Subject Participations - DM and DC domains

CDASH – Aligning with SDTMIG v3.4 including GF and CP domains

SEND - Implementing new domains including IS, CP, PI, OE, and SX

Medical Devices – Addressing how to represent multiple device components




# ICH M11:Clinical Electronic Structured Harmonised Protocol Components

The **Technical Specification** presents the conformance, cardinality, and other technical attributes that enable the interoperable electronic exchange of protocol content



The **Template** presents the format and structure of the protocol, including the table of contents, common headers, and contents





## **Template for Description of Trial Design**


#### 4.1 Description of Trial Design

Describe the trial intervention model (for example, single group, parallel group, cross-over, factorial, sequential), the expected number of participants, and the control method (for example, placebo, active comparator, low dose, historical, standard of care, sham procedure, or none [uncontrolled]).

If applicable, indicate the type of trial (for example, superiority, non-inferiority, dose escalation, or equivalence).



## **Technical Specification for Description of Trial Design**



- Variables
- Concept/Terminology
- Code lists
- Conformance



### **Role of CDISC**

- Govern controlled terminology, code lists, content nomenclature
- Define content model to represent content agnostic of exchange standard
- Determine conformance rules for M11 model
- Work directly with ICH M11 on defining mappings between M11 model and CDISC Standards and Artifacts
- → Longer term view for CDISC to publish the model
  - ICH will remain the authority, CDISC will govern the terminology





## Learn more about ICH M11!

Session 6: Track A- Updates Towards Regulatory

11:00 - 13:00



# Digital Data Flow Project





- Collaborative development project with TransCelerate Biopharma, Stakeholders, Vendors and CDISC
- Creation of the Unified Study Definitions Model (USDM) Reference Architecture and an open source Reference Implementation of this Architecture called the Study Definitions Repository (SDR)

#### Goals:

- To enable the format of information from a digitized protocol and other sources to be standardized and stored centrally
- Allow information to be passed to systems used for study execution and data collection and reused throughout the clinical development lifecycle



## Learn more about DDF!

Session 7: Track B- Digital Data Flow


14:00 - 16:00





## **Data Sources**

#### **Real World Data**





## **RWD** and the Regulatory Environment

China's NMPA



US FDA



**EU EMA** 



Exploring and promoting the use of highquality RWD in decision-making as a strategic goal



http://www.cde.org.cn/news.do?method=largeInfo&id=23a2b4cbe0807fe2

#22 49 2578852#881249 #6 10022 #E MILANSSON #E MILANSSON \$EFF 200780012725

https://www.fda.gov/media/120060/download

https://www.ema.europa.eu/en/document s/regulatory-procedural-guideline/emaregulatory-science-2025-strategicreflection\_en.pdf Japan's PMDA



Utilization of Real World Data
- PMDA's approaches -

23rd March, 2021

Health-related data are gathered and accumulated in the clinical practice day by day. These data are called Real World Data (RWD), and they include electronic health record, claims data, patient registry data, etc. RWD still provide valuable information related to the outcomes of using modical products, while RWD are not obtained in the same manner as well-designed clinical trials conducted to evaluate modical products.

At PMDA, we have already had some experiences of utilizing such existing data for evaluating benefit-risk balance in the regulatory process. For example, in the case of sacrolimus, RWD was utilized in its approval for an indication supplement of initial treatment for interstitial pneumonia associated with polymyositis/dematomyositis. The indication was approved in 2013. Not only above case, but RWD has been utilized in some of new day applications so far.

Although the PMDA has been making good use of RWD, it applied a case-by-case basis approach until recently. It might not be widely known RWD can be utilized for regulatory submission. In order to promote RWD utilization further by product developers, the PMDA has recently developed and finalized two guidelines below:

https://www.pmda.go.jp/english/about-pmda/0004.pdf



## **HL7 FHIR to CDISC Mapping**

- Fast Healthcare Interoperability Resources (FHIR) is a standard published by HL7 for exchanging healthcare information electronically
- Goal of mapping is to achieve greater interoperability and exchange of data from Electronic Health Records (EHRs) to clinical research submission-ready datasets
- Scope: Adverse Events, Medications, Concomitant Medications, Demographics, Medical History, Procedures, Vital Signs, Laboratory Test Results
- Mappings jointly balloted by CDISC and HL7 using their respective governance processes










# DRAG N: An IMI-Funded Project

Develop Al-enhanced tools for evaluating COVID patients' *CT scans* and *clinical data* to provide accurate diagnoses and predict patient outcome.



## Considerations for Using CDISC Standards for Observational Studies

#### Goal

- To publish a CDISC-endorsed approach to working with observational research data
- Provide a "stake in the ground" for future expansion

#### Scope of Use Cases

- Observational Research Studies
  - Cross-sectional studies
  - Cohort studies
- Clinical trials: external control arm using RWD

#### **Development Scope**

- SDTM for now
- CDASH, ADaM could come in subsequent version







### **Increased Regulatory Focus on Digital Health Technologies**

# FDA | CDER | Small Business and Industry Assistance INDUSTRY NEWS

#### FDA to Host Digital Health Technologies for Drugs Public Workshop


The U.S. Food and Drug Administration is hosting the virtual public workshop "Understanding Priorities for the Development of Digital Health Technologies to Support Clinical Trials for Drug Development and Review" on March 28th and 29th, 2023. The workshop will focus on understanding the priorities and challenges of developing Digital Health Technologies (DHTs) to support clinical drug trials.

The workshop will be convened by the Robert J. Margolis, MD, Center for Health Policy at Duke University under a cooperative agreement with FDA.

For more information on the Digital Health Technologies virtual public workshop and to register, please visit FDA's Meeting's, Conferences & Workshops (Drugs).



## **CDISC Standards Are Robust Enough to Represent DHT Data**





# **Device SDTM Domains**

Intended to support most or all types of devices

Device Identifiers (DI)	<ul> <li>Consistent unique sponsor-defined identifier that links data across domains.</li> </ul>
Device Properties (DO)	<ul> <li>Important unvarying device characteristics that are not identifiers</li> </ul>
Device-In-Use (DU)	<ul> <li>Measurements and settings intentionally set that may vary between uses of a device</li> </ul>
Device Exposure (DX)	Subject's exposure to a medical device under study
Device Events (DE)	<ul> <li>Reportable device-related occurrences such as malfunctions and calibrations</li> </ul>
Tracking and Disposition (DT)	<ul> <li>Physical locations of device, either at each movement or just final status</li> </ul>
Device-Subject Relationship (DR)	<ul> <li>Look-up table providing single consistent link between each device and subject</li> </ul>



# **CDISC DHT Team: Proposed Scope**

- Identify domains for the commonly generated measurements from passive monitoring and active tests
- Define Controlled Terminologies and Codetable Mapping Files for the commonly used digital endpoints



- Adoption of SDTMIG for Medical Device to accommodate DHT needs
- Release the first draft for Public Review





# Learn more about CDISC and RWD Data!

Session 4: Track A- Real World Data

16:00 - 18:00

Session 7: Track C- CDISC Foundational, Part II 14:00 - 15:30



https://www.cdisc.org/standards/real-world-data



# **Study Execution**

# What is Dataset-JSON and Advantages

#### What is JSON?


An open standard file format and data interchange format that uses human-readable text to store and transmit data objects consisting of attribute–value pairs and arrays

#### What is Dataset-JSON?

A dataset exchange standard for exchanging tabular data leveraging JSON designed to meet the regulatory submission needs and eliminating limitations of legacy formats

#### Dataset-JSON advantages...

- Based on the JSON standard used worldwide
- Open-source and truly human readable
- Same or smaller file sizes relative to current required format
- Remove variable naming, width, or format limitations
- Simple transformation to/from SAS data





## **Proposed Dataset-JSON Pilot**





#### **Milestone 1: Short Term**

- Pilot submissions using JSON format with existing XPT ingress/egress to carry the same data
- Same content, different suitcase, no disruption to business process on either side
- In parallel, evaluate how FDA toolset can support JSON format and identify tool upgrade roadmap
- → Success Criteria: Accept Dataset-JSON as a transport format option (in addition to existing XPT format)

#### Milestone 2: Long Term

- Enhance the CDISC SDTM and ADaM standards beyond XPT limitations (e.g. Variable names > 8, labels > 40, data > 200
- New Define-XML / Define-JSON based on ODM v2.0
- Enhanced conformance rules
- Collaborate with FDA to develop plan to retool their environment to natively consume JSON
- → Success Criteria: accept advanced Dataset-JSON as the only transport format option and deprecate XPT



## **ODM v2.0**

- ODM-XML is a vendor-neutral, platform-independent format for exchanging and archiving clinical and translational research data, along with their associated metadata
- The ODM v2.0 vision is to build on ODM's proven strength and improved support for automation.
  - improved alignment with CDISC Foundational Standards as well as healthcare standards such as HL7 FHIR.
  - support for multiple media types (XML and JSON), enhanced semantics, the Study Design Model, data queries, more flexible data structure representations, and operational data set



Completed Public Review – final publication scheduled for July 2023



# **CDISC Open Source Alliance**

Supports, promotes, and sometimes sponsors open-source software projects that create tools for implementing or developing CDISC standards to drive innovation in the CDISC community





























https://cosa.cdisc.org

# Why is CDISC doing CORE?

- Ensure each standard has a set of unambiguous, executable Conformance Rules
- Ensure consistency across Conformance Rule implementations
- Expedite the availability of executable Conformance Rules for new Foundational Standards
- Create executable Conformance Rules vetted by the CDISC standards development teams
- Develop an open-source engine that serves as a Reference Implementation
- Publish the Rules in the CDISC Library and the engine under the CDISC Open Source Alliance (COSA)



https://www.cdisc.org/core



# Learn more about CORE!

Session 6: Track B- CORE Implementation

11:00 - 13:00

Session 5: Track B- Core Rules Development

9:00 - 10:30





### What is the Trial Master File?


The sponsor and the investigator shall keep a clinical **trial master file**. The clinical trial master file shall at all times contain the **essential documents** relating to that clinical trial which allow verification of the conduct of a clinical trial and the quality of the data generated [...]. It shall be readily available, and directly accessible upon request, to the Member States.

[EU Regulation 536/2014]

## What is the Trial Master File Reference Model?

A Standardised structure, contents and naming of these Essential documents

2022 Survey: Organizations using TMF Reference Model





## **TMF** Initiatives

The Education Team

The Standards Team

The CDISC TMF Interchange!





**NEW ANNUAL CONFERENCE** 

# 2023 CDISC TMF INTERCHANGE

28-29 SEPTEMBER BALTIMORE






# **Learn more about TMF!**

Session 8: Closing Plenary

16:15 - 16:45






# **Relentless Collaboration**







Thank you!

